Bharat Biotech complete enrollment of 25,800 volunteers for Covaxin Phase-3 trials

Bharat Biotech has completedenrollment of 25,800 volunteers for the Phase-3 trials of itsCOVID-19 vaccine Covaxin, Suchitra Ella, joint managingdirector, Bharat Biotech International Ltd said on Thursday.

In a message posted on the company's Twitter account,she thanked clinical trial sites, principal investigators andhealth workers for their support and trust in the ''public-private partnership'' vaccine discovery.

''My deep appreciation to all the volunteers forreposing and expressing Pro Vaccine Public Health Voluntarismin the phase-3 clinical trials of India's 1st fully indigenousCOVID-19 vaccine,'' she said referring to Covaxin.

The Drug Controller General of India (DCGI) hasrecently given Emergency Use Authorisation for Covaxin.

The Phase III human clinical trials of Covaxin beganmid-November, targeted to be done in 26,000 volunteersacrossIndia.

The company had said it is the only Phase-3 efficacystudy for a COVID-19 vaccine, and the largest efficacy trial(Phase-3) ever conducted for any vaccine in India.PTI GDK SSPTI PTI